Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial

Post time 2026-6-12 23:23:35

journal：Stroke

Authors：Xinyan Hu; Qianmei Jiang; Ning Wang; Qi Liu; Shilin Li; Pengzhan Wang; Chen Ling; Anxin Wang; Zhe Zhang; Jianying Cao; Xinjian Yang; Yongjun Wang; Xuewei Xie; Jing Jing; Lian Liu

Published date：--

DOI：10.1161/strokeaha.126.056558

PDF link：https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.126.056558

Article link：https://doi.org/10.1161/strokeaha.126.056558

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2026-6-12 23:23:36

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AHA] Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial